Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

High Rates of Varicella Zoster Virus Antibody Seroconversion and Persistence after Administration of the Adjuvanted, Recombinant Varicella Zoster Vaccine in Multiple Myeloma Patients Undergoing Active Treatment

Karen Sweiss, PharmD, Gregory Sampang Calip, PharmD,MPH,PhD, Damiano Rondelli, MD, Pritesh Patel, MB, ChB

Blood (2020) 136 (Supplement 1): 50.

https://doi.org/10.1182/blood-2020-143342

Published: 2020

Journal Articles

Comparison of Individualized Versus MAP-Bayesian Predicted AUC of Busulfan in FluBu4 Treated Patients Undergoing Allogeneic Transplant

Karen Sweiss, PharmD, Eric Wenzler, Hung H Nguyen, MLS, Avadhut D Joshi, PhD, Rosa Yeh, PharmD, Gregory Sampang Calip, PharmD,MPH,PhD, Jeremy Johnson, PharmD, PhD, Donald Irby, PhD, Mitch A. Phelps, PhD, Damiano Rondelli, MD, Pritesh Patel, MB, ChB

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-143430

Published: 2020

Journal Articles

Increased DNA Repair Gene Expression Correlates with MYC Expression and Inferior Progression-Free Survival in Multiple Myeloma Patients

Karen Sweiss, PharmD, Benjamin G Barwick, PhD, Gregory Sampang Calip, PharmD,MPH,PhD, Damiano Rondelli, MD, Craig C Hofmeister, MDMPH, Pritesh Patel, MB, ChB

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-143422

Published: 2020

Journal Articles

Low Pre-Treatment Hemoglobin and Creatinine Clearance Correlate with Worse Overall Survival, Treatment-Related Mortality, and Regimen-Related Toxicities in Patients Undergoing a Reduced-Intensity Allogeneic Stem Cell Transplantation with Fludarabine and Melphalan

Karen Sweiss, PharmD, Gregory Sampang Calip, PharmD,MPH,PhD, Jeremy Johnson, PharmD, PhD, Jaime Holden, BFA, Paulina Lewkowski, BS, Iryna Mialik, AS, John P Galvin, MDMS,MPH, Damiano Rondelli, MD, Pritesh Patel, MB, ChB

Blood (2019) 134 (Supplement_1): 1980.

https://doi.org/10.1182/blood-2019-131886

Published: 2019

Journal Articles

High Rates of Varicella Zoster Virus Antibody Seroconversion after Administration of the Adjuvanted, Recombinant Varicella Zoster Vaccine in Multiple Myeloma Patients Undergoing Active Treatment

Karen Sweiss, PharmD, Gregory Sampang Calip, PharmD,MPH,PhD, John P Galvin, MDMS,MPH, Damiano Rondelli, MD, Pritesh Patel, MB, ChB

Blood (2019) 134 (Supplement_1): 3081.

https://doi.org/10.1182/blood-2019-131914

Published: 2019

Journal Articles

Development of a Real Time Pharmacokinetic Testing Method to Allow for Targeted Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Transplant

Karen Sweiss, PharmD, Bhaskar Vemu, PhD, Gregory Sampang Calip, PharmD,MPH,PhD, John P Galvin, MDMS,MPH, John G. Quigley, Nadim Mahmud, MBBS, PhD, Damiano Rondelli, MD, Jeremy Johnson, PharmD, PhD, Pritesh Patel, MB, ChB

Blood (2019) 134 (Supplement_1): 3310.

https://doi.org/10.1182/blood-2019-132216

Published: 2019

Journal Articles

Health Care Utilization in Transplanted Versus Non-Transplanted Sickle Cell Disease Patients

Santosh L. Saraf, MD, Krishna Ghimire, MD, Pritesh Patel, MD, Karen Sweiss, PharmD, John G. Quigley, Irum Khan, MBBS, David Peace, MD, Michel Gowhari, DO, Shivi Jain, MD, John P. Galvin, MDMS,MPH, Robert E. Molokie, MD, Victor R. Gordeuk, MD, Damiano Rondelli, MD

Blood (2018) 132 (Supplement 1): 313.

https://doi.org/10.1182/blood-2018-99-113666

Published: 2018

Journal Articles

A New Prognostic Score Using Lymphocyte to Monocyte Ratio and Immunoglobulin Levels to Predict Progression in Multiple Myeloma Patients Undergoing Autologous Transplant

Karen Sweiss, PharmD, Gregory Sampang Calip, PharmD, MPH, PhD, Jonathan Lee, Nadim Mahmud, MBBS, PhD, Damiano Rondelli, MD, Pritesh Patel, MD

Blood (2018) 132 (Supplement 1): 3442.

https://doi.org/10.1182/blood-2018-99-118965

Published: 2018

Journal Articles

A Safety Study of the Addition of Omacetaxine to the Standard-of-Care Induction Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients

Sonia Christian, MD, Kelley E. Kozma, DO, Stephanie Barath, Ardaman Shergill, MD, Damiano Rondelli, MD, David Peace, MD, Santosh L. Saraf, MD, Annie Lee Oh, MD, Karen Sweiss, PharmD, Irum Khan, MBBS, Pritesh Patel, MD, Arkadiusz Dudek, MD PhD, John G. Quigley

Blood (2018) 132 (Supplement 1): 5218.

https://doi.org/10.1182/blood-2018-99-111412

Published: 2018

Journal Articles

Arterial and Venous Thromboembolic Safety of Bevacizumab in Patients with High Grade Gliomas

Inyoung Lee, MS, BPharm, Sruthi Adimadhyam, BPharm, MS, Edith A. Nutescu, PharmD., MS, FCCP, Karen Sweiss, PharmD, Pritesh Patel, MD, Gregory Sampang Calip, PharmD, MPH, PhD

Blood (2018) 132 (Supplement 1): 2280.

https://doi.org/10.1182/blood-2018-99-116938

Published: 2018

Journal Articles

Venous Thromboembolic Prophylaxis Following Treatment Initiation for Multiple Myeloma

Gregory Sampang Calip, PharmD, MPH, PhD, Jifang Zhou, MD, Karen Sweiss, PharmD, Pritesh Patel, MD, Alemseged Ayele Asfaw, MSc, B Pharm, Todd Lee, PharmD, PhD, Brian C.-H. Chiu, PhD, Edith A. Nutescu, PharmD., MS, FCCP

Blood (2018) 132 (Supplement 1): 4693.

https://doi.org/10.1182/blood-2018-99-116867

Published: 2018

Journal Articles

Pre-Transplant Hemoglobin and Creatinine Clearance Correlate with Treatment Free Survival in Patients with Myeloma Receiving Mel200 and Autologous Stem Cell Transplantation

Karen Sweiss, PharmD, Gregory Sampang Calip, PharmD, MPH, PhD, Jeremy Johnson, PharmD, PhD, Hyunyoung Jeong, PharmD, PhD, Damiano Rondelli, MD, Pritesh Patel, MD

Blood (2018) 132 (Supplement 1): 4621.

https://doi.org/10.1182/blood-2018-99-117623

Published: 2018

Journal Articles

A Multi-Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) Vs High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Sonia Christian, MD, Pritesh Patel, MD, Vaibhav Agrawal, MD MBA, Shawn Griffin, PharmD, Kirk Cahill, MD, Irum Khan, MBBS, Karen Sweiss, PharmD, Ardaman Shergill, MD, Gregory Sampang Calip, PharmD,MPH,PhD, Wendy Stock, MD, Olatoyosi Odenike, MD, Heiko Konig, MDPhD, John G. Quigley

Blood (2018) 132 (Supplement 1): 1397.

https://doi.org/10.1182/blood-2018-99-111389

Published: 2018

Journal Articles

Collaborative Physician-Pharmacist Managed Multiple Myeloma Clinic Decreases Polypharmacy, Improves Guideline Adherence, and Prevents Treatment Delays

Karen Sweiss, PharmD, Gregory Sampang Calip, PharmD, MPH, PhD, Scott Wirth, PharmD, Damiano Rondelli, MD, Pritesh Patel, MD

Blood (2018) 132 (Supplement 1): 3542.

https://doi.org/10.1182/blood-2018-99-117657

Published: 2018

Journal Articles

Biologic Disease-Modifying Antirheumatic Drugs and Risk of Multiple Myeloma

Gregory Sampang Calip, PharmD, MPH, PhD, Karen Sweiss, PharmD, Sruthi Adimadhyam, BPharm, MS, Alemseged Ayele Asfaw, MSc, B Pharm, Jifang Zhou, MD, Zhaoju Wu, MD PhD, Todd Lee, PharmD, PhD, Brian C.-H. Chiu, PhD, Pritesh Patel, MD

Blood (2018) 132 (Supplement 1): 1888.

https://doi.org/10.1182/blood-2018-99-116412

Published: 2018

Journal Articles

A Single Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) Vs High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) for Treatment of Patients with Relapsed or Refractory Acute Myeloid Leukemia

Sonia Christian, MD, Pritesh Patel, MB, CHB, Aysenur Esen, MD, Irum Khan, MBBS, Karen Sweiss, PharmD, Fares Ghanem, MD, Christopher A. Sequeira, MD, Ardaman Shergill, MD, John G. Quigley, MD

Blood (2017) 130 (Supplement 1): 2591.

https://doi.org/10.1182/blood.V130.Suppl_1.2591.2591

Published: 2017

Journal Articles

Collaborative Physician-Pharmacist Multiple Myeloma Clinic Improves Guideline Adherence and Prevents Treatment Delays

Karen Sweiss, PharmD, Scott Wirth, PharmD, Irene Park, Helen Sweiss, Pritesh Patel, MB, CHB

Blood (2017) 130 (Supplement 1): 2112.

https://doi.org/10.1182/blood.V130.Suppl_1.2112.2112

Published: 2017

Journal Articles

Combined Immune Score of Lymphocyte to Monocyte Ratio and Immunoglobulin Levels Predicts Progression-Free Survival of Myeloma Patients after Autologous Transplant

Karen Sweiss, PharmD, Jonathan Lee, Annie L. Oh, MD, Gregory Sampang Calip, PharmD,MPH,PhD, Nadim Mahmud, MBBS, PhD, Damiano Rondelli, MD, Pritesh Patel, MB, CHB

Blood (2017) 130 (Supplement 1): 2012.

https://doi.org/10.1182/blood.V130.Suppl_1.2012.2012

Published: 2017

Journal Articles

Acute Kidney Injury before Day 90 Predicts for Both Early and Late Mortality after FluBu4

Karen Sweiss, PharmD, Annie L. Oh, MD, John G. Quigley, MD, Gregory Sampang Calip, PharmD,MPH,PhD, Damiano Rondelli, MD, Pritesh Patel, MB, CHB

Blood (2017) 130 (Supplement 1): 1941.

https://doi.org/10.1182/blood.V130.Suppl_1.1941.1941

Published: 2017

Journal Articles

Similar Survival but Increased Toxicity with a Sequential Versus Concurrent FluBu4 Regimen

Karen Sweiss, PharmD, Annie L. Oh, MD, Gregory Sampang Calip, PharmD,MPH,PhD, John G. Quigley, MD, Damiano Rondelli, MD, Pritesh Patel, MB, CHB

Blood (2017) 130 (Supplement 1): 1942.

https://doi.org/10.1182/blood.V130.Suppl_1.1942.1942

Published: 2017

NARROW

High Rates of Varicella Zoster Virus Antibody Seroconversion and Persistence after Administration of the Adjuvanted, Recombinant Varicella Zoster Vaccine in Multiple Myeloma Patients Undergoing Active Treatment

Comparison of Individualized Versus MAP-Bayesian Predicted AUC of Busulfan in FluBu4 Treated Patients Undergoing Allogeneic Transplant

Increased DNA Repair Gene Expression Correlates with MYC Expression and Inferior Progression-Free Survival in Multiple Myeloma Patients

Low Pre-Treatment Hemoglobin and Creatinine Clearance Correlate with Worse Overall Survival, Treatment-Related Mortality, and Regimen-Related Toxicities in Patients Undergoing a Reduced-Intensity Allogeneic Stem Cell Transplantation with Fludarabine and Melphalan

High Rates of Varicella Zoster Virus Antibody Seroconversion after Administration of the Adjuvanted, Recombinant Varicella Zoster Vaccine in Multiple Myeloma Patients Undergoing Active Treatment

Development of a Real Time Pharmacokinetic Testing Method to Allow for Targeted Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Transplant

Health Care Utilization in Transplanted Versus Non-Transplanted Sickle Cell Disease Patients

A New Prognostic Score Using Lymphocyte to Monocyte Ratio and Immunoglobulin Levels to Predict Progression in Multiple Myeloma Patients Undergoing Autologous Transplant

A Safety Study of the Addition of Omacetaxine to the Standard-of-Care Induction Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients

Arterial and Venous Thromboembolic Safety of Bevacizumab in Patients with High Grade Gliomas

Venous Thromboembolic Prophylaxis Following Treatment Initiation for Multiple Myeloma

Pre-Transplant Hemoglobin and Creatinine Clearance Correlate with Treatment Free Survival in Patients with Myeloma Receiving Mel200 and Autologous Stem Cell Transplantation

A Multi-Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) Vs High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Collaborative Physician-Pharmacist Managed Multiple Myeloma Clinic Decreases Polypharmacy, Improves Guideline Adherence, and Prevents Treatment Delays

Biologic Disease-Modifying Antirheumatic Drugs and Risk of Multiple Myeloma

A Single Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) Vs High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) for Treatment of Patients with Relapsed or Refractory Acute Myeloid Leukemia

Collaborative Physician-Pharmacist Multiple Myeloma Clinic Improves Guideline Adherence and Prevents Treatment Delays

Combined Immune Score of Lymphocyte to Monocyte Ratio and Immunoglobulin Levels Predicts Progression-Free Survival of Myeloma Patients after Autologous Transplant

Acute Kidney Injury before Day 90 Predicts for Both Early and Late Mortality after FluBu4

Similar Survival but Increased Toxicity with a Sequential Versus Concurrent FluBu4 Regimen

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only